elexacaftor, ivacaftor, tezacaftor; ivacaftor · Vertex Pharms Inc · NDA 212273, 217660
Trikafta (Copackaged)
Other strengths are listed to 17 Jul 2038.
Blocked by patent: US 10793547, US 10793547, US 10793547, US 10793547, US 10793547, US 10793547, US 10793547, US 11179367, US 11179367, US 11179367, US 11179367, US 11179367, US 11179367, US 11453655, US 11517564, US 11517564, US 11517564, US 11517564, US 11517564, US 11517564, US 11517564.
Listed patents · 141 unexpired
| Patent | Claims | Expires |
|---|---|---|
| US 12350262 | use U-4222 | 17 Jul 2038 |
| US 12350262 | use U-4221 | 17 Jul 2038 |
| US 12350262 | use U-4220 | 17 Jul 2038 |
| US 12350262 | use U-4476 | 17 Jul 2038 |
| US 12350262 | use U-4475 | 17 Jul 2038 |
| US 10793547 | substance, product, use U-3144 | 8 Dec 2037 |
| US 10793547 | substance, product, use U-3588 | 8 Dec 2037 |
| US 10793547 | substance, product, use U-3028 | 8 Dec 2037 |
| US 10793547 | substance, product, use U-4066 | 8 Dec 2037 |
| US 10793547 | substance, product, use U-4475 | 8 Dec 2037 |
| US 10793547 | substance, product, use U-4476 | 8 Dec 2037 |
| US 10793547 | substance, product, use U-4073 | 8 Dec 2037 |
| US 11179367 | product, use U-4071 | 8 Dec 2037 |
| US 11179367 | product, use U-4484 | 8 Dec 2037 |
| US 11179367 | product, use U-3597 | 8 Dec 2037 |
| US 11179367 | product, use U-4487 | 8 Dec 2037 |
| US 11179367 | product, use U-3253 | 8 Dec 2037 |
| US 11179367 | product, use U-4059 | 8 Dec 2037 |
| US 11453655 | substance, product | 8 Dec 2037 |
| US 11517564 | product, use U-4057 | 8 Dec 2037 |
| US 11517564 | product, use U-4475 | 8 Dec 2037 |
| US 11517564 | product, use U-4476 | 8 Dec 2037 |
| US 11517564 | product, use U-3586 | 8 Dec 2037 |
| US 11517564 | product, use U-4069 | 8 Dec 2037 |
| US 11517564 | product, use U-4067 | 8 Dec 2037 |
| US 11517564 | product, use U-3498 | 8 Dec 2037 |
| US 10758534 | substance, product, use U-3144 | 6 Oct 2035 |
| US 10758534 | substance, product, use U-3589 | 6 Oct 2035 |
| US 10758534 | substance, product, use U-3028 | 6 Oct 2035 |
| US 10758534 | substance, product, use U-4066 | 6 Oct 2035 |
| US 10758534 | substance, product, use U-4475 | 6 Oct 2035 |
| US 10758534 | substance, product, use U-4073 | 6 Oct 2035 |
| US 10758534 | substance, product, use U-4476 | 6 Oct 2035 |
| US 11426407 | substance, product, use U-3425 | 6 Oct 2035 |
| US 11426407 | substance, product, use U-4475 | 6 Oct 2035 |
| US 11426407 | substance, product, use U-4058 | 6 Oct 2035 |
| US 11426407 | substance, product, use U-4476 | 6 Oct 2035 |
| US 11426407 | substance, product, use U-4070 | 6 Oct 2035 |
| US 11426407 | substance, product, use U-3595 | 6 Oct 2035 |
| US 9012496 | use U-2649 | 15 Jul 2033 |
| US 9012496 | use U-3154 | 15 Jul 2033 |
| US 10272046 | product, use U-4062 | 27 Feb 2033 |
| US 10272046 | product, use U-4482 | 27 Feb 2033 |
| US 10272046 | product, use U-3599 | 27 Feb 2033 |
| US 11147770 | product, use U-4483 | 27 Feb 2033 |
| US 11147770 | product, use U-3598 | 27 Feb 2033 |
| US 11147770 | product, use U-4060 | 27 Feb 2033 |
| US 11752106 | product, use U-4489 | 27 Feb 2033 |
| US 11752106 | product, use U-4052 | 27 Feb 2033 |
| US 11752106 | product, use U-3696 | 27 Feb 2033 |
| US 12214083 | product, use U-4492 | 27 Feb 2033 |
| US 12214083 | product, use U-4141 | 27 Feb 2033 |
| US 8883206 | product | 27 Feb 2033 |
| US RE50453 | substance, product | 10 Jul 2031 |
| US 10081621 | product, use U-3600 | 25 Mar 2031 |
| US 10081621 | product, use U-4480 | 25 Mar 2031 |
| US 10081621 | product, use U-4481 | 25 Mar 2031 |
| US 10081621 | product, use U-4075 | 25 Mar 2031 |
| US 10081621 | product, use U-4065 | 25 Mar 2031 |
| US 10081621 | product, use U-3032 | 25 Mar 2031 |
| US 10081621 | product, use U-3157 | 25 Mar 2031 |
| US 11578062 | product, use U-4054 | 25 Mar 2031 |
| US 11578062 | product, use U-4490 | 25 Mar 2031 |
| US 11578062 | product, use U-3584 | 25 Mar 2031 |
| US 11578062 | product, use U-4488 | 25 Mar 2031 |
| US 11578062 | product, use U-3544 | 25 Mar 2031 |
| US 10646481 | product | 13 Aug 2029 |
| US 11564916 | use U-4491 | 13 Aug 2029 |
| US 11564916 | use U-3525 | 13 Aug 2029 |
| US 11564916 | use U-4063 | 13 Aug 2029 |
| US 11564916 | use U-4055 | 13 Aug 2029 |
| US 11564916 | use U-3585 | 13 Aug 2029 |
| US 11564916 | use U-4485 | 13 Aug 2029 |
| US 12458635 | product, use U-4486 | 13 Aug 2029 |
| US 12458635 | product, use U-4330 | 13 Aug 2029 |
| US 12458635 | product, use U-4493 | 13 Aug 2029 |
| US 12458635 | product, use U-4333 | 13 Aug 2029 |
| US 8415387 | use U-4066 | 12 Nov 2027 |
| US 8415387 | use U-3144 | 12 Nov 2027 |
| US 8415387 | use U-4476 | 12 Nov 2027 |
| US 8415387 | use U-4073 | 12 Nov 2027 |
| US 8415387 | use U-4475 | 12 Nov 2027 |
| US 8415387 | use U-3589 | 12 Nov 2027 |
| US 8415387 | use U-3028 | 12 Nov 2027 |
| US 8324242 | use U-4475 | 5 Aug 2027 |
| US 8324242 | use U-3589 | 5 Aug 2027 |
| US 8324242 | use U-3144 | 5 Aug 2027 |
| US 8324242 | use U-4066 | 5 Aug 2027 |
| US 8324242 | use U-4073 | 5 Aug 2027 |
| US 8324242 | use U-4476 | 5 Aug 2027 |
| US 8324242 | use U-3028 | 5 Aug 2027 |
| US 7776905 | substance, product | 3 Jun 2027 |
| US 7495103 | substance, product | 20 May 2027 |
| US 7645789 | substance, product | 1 May 2027 |
| US 8598181 | use U-4476 | 1 May 2027 |
| US 8598181 | use U-3144 | 1 May 2027 |
| US 8598181 | use U-4056 | 1 May 2027 |
| US 8598181 | use U-3028 | 1 May 2027 |
| US 8598181 | use U-3589 | 1 May 2027 |
| US 8598181 | use U-4475 | 1 May 2027 |
| US 8598181 | use U-4066 | 1 May 2027 |
| US 8623905 | substance, product | 1 May 2027 |
| US 10022352 | product, use U-2651 | 9 Apr 2027 |
| US 10022352 | product, use U-3596 | 9 Apr 2027 |
| US 10022352 | product, use U-3156 | 9 Apr 2027 |
| US 10239867 | substance, product, use U-4476 | 9 Apr 2027 |
| US 10239867 | substance, product, use U-4475 | 9 Apr 2027 |
| US 10239867 | substance, product, use U-3033 | 9 Apr 2027 |
| US 10239867 | substance, product, use U-4053 | 9 Apr 2027 |
| US 10239867 | substance, product, use U-4056 | 9 Apr 2027 |
| US 10239867 | substance, product, use U-3158 | 9 Apr 2027 |
| US 10239867 | substance, product, use U-3590 | 9 Apr 2027 |
| US 11639347 | substance, product, use U-4476 | 9 Apr 2027 |
| US 11639347 | substance, product, use U-3587 | 9 Apr 2027 |
| US 11639347 | substance, product, use U-4056 | 9 Apr 2027 |
| US 11639347 | substance, product, use U-3583 | 9 Apr 2027 |
| US 11639347 | substance, product, use U-4053 | 9 Apr 2027 |
| US 11639347 | substance, product, use U-4475 | 9 Apr 2027 |
| US 9974781 | product, use U-4066 | 9 Apr 2027 |
| US 9974781 | product, use U-4073 | 9 Apr 2027 |
| US 9974781 | product, use U-4476 | 9 Apr 2027 |
| US 9974781 | product, use U-4475 | 9 Apr 2027 |
| US 9974781 | product, use U-3144 | 9 Apr 2027 |
| US 9974781 | product, use U-3589 | 9 Apr 2027 |
| US 9974781 | product, use U-3028 | 9 Apr 2027 |
| US 8410274 | product | 28 Dec 2026 |
| US 8754224 | substance, product | 28 Dec 2026 |
| US 9670163 | product, use U-4068 | 28 Dec 2026 |
| US 9670163 | product, use U-4478 | 28 Dec 2026 |
| US 9670163 | product, use U-4477 | 28 Dec 2026 |
| US 9670163 | product, use U-4078 | 28 Dec 2026 |
| US 9670163 | product, use U-3591 | 28 Dec 2026 |
| US 9670163 | product, use U-3031 | 28 Dec 2026 |
| US 9670163 | product, use U-3155 | 28 Dec 2026 |
| US 9931334 | product, use U-4078 | 28 Dec 2026 |
| US 9931334 | product, use U-4479 | 28 Dec 2026 |
| US 9931334 | product, use U-3031 | 28 Dec 2026 |
| US 9931334 | product, use U-3591 | 28 Dec 2026 |
| US 9931334 | product, use U-4478 | 28 Dec 2026 |
| US 9931334 | product, use U-3155 | 28 Dec 2026 |
| US 9931334 | product, use U-4068 | 28 Dec 2026 |
Exclusivities · 7 unexpired
| ODE-543 | orphan drug (7 years) | 27 Mar 2033 |
| ODE-512 | orphan drug (7 years) | 20 Dec 2031 |
| ODE-433 | orphan drug (7 years) | 26 Apr 2030 |
| ODE-357 | orphan drug (7 years) | 8 Jun 2028 |
| ODE* | 21 Dec 2027 | |
| ODE-323 | orphan drug (7 years) | 21 Dec 2027 |
| M-313 | miscellaneous (3 years) | 20 Dec 2027 |
Paragraph IV certifications · 0
No Paragraph IV certification listed by FDA for this drug.
The list shows that a generic applicant certified to FDA that a listed patent is invalid or not infringed. It does not show litigation, settlements or launch timing.
Event history
No events yet. The first ingestion only records products entering their 12-month window; changes appear from the next Orange Book update.
Products covered · 4
| NDA · product | Form | Strength | Listed expiry |
|---|---|---|---|
| 212273 · 001 · RLD | tablet, oral | 100MG,75MG,50MG; 150MG | 17 Jul 2038 |
| 212273 · 002 · RLD | tablet, oral | 50MG,37.5MG,25MG; 75MG | 17 Jul 2038 |
| 217660 · 001 · RLD | granule, oral | 80MG, 60MG, 40MG;59.5MG | 8 Dec 2037 |
| 217660 · 002 · RLD | granule, oral | 100MG, 75MG, 50MG;75MG | 17 Jul 2038 |
Expired or delisted (6)
- US 8354427 · use U-3145 · 6 Jul 2026
- US 8354427 · use U-3593 · 6 Jul 2026
- US 8354427 · use U-3029 · 6 Jul 2026
- ODE-275 · 21 Oct 2026
- ODE* · 21 Oct 2026
- NP · 26 Apr 2026